Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Open accessThe DOI matches its Crossref record; 220 of the 220 references it cites were found in a registry or an index; 89 of the 278 sources its claims cite were checked for support.
Abstract
Studies on psychotropic medications decrease, discontinuation, or switch have uncovered withdrawal syndromes. The present overview aimed at analyzing the literature to illustrate withdrawal after decrease, discontinuation, or switch of psychotropic medications based on the drug class (i.e., benzodiazepines, nonbenzodiazepine benzodiazepine receptor agonists, antidepressants, ketamine, antipsychotics, lithium, mood stabilizers) according to the diagnostic criteria of Chouinard and Chouinard [Psychother Psychosom. 2015;84(2):63-71], which encompass new withdrawal symptoms, rebound symptoms, and persistent post-withdrawal disorders. All these drugs may induce withdrawal syndromes and rebound upon discontinuation, even with slow tapering. However, only selective serotonin reuptake inhibitors, serotonin noradrenaline reuptake inhibitors, and antipsychotics were consistently also associated with persistent post-withdrawal disorders and potential high severity of symptoms, including alterations of clinical course, whereas the distress associated with benzodiazepines discontinuation appears to be short-lived. As a result, the common belief that benzodiazepines should be substituted by medications that cause less dependence such as antidepressants and antipsychotics runs counter the available literature. Ketamine, and probably its derivatives, may be classified as at high risk for dependence and addiction. Because of the lag phase that has taken place between the introduction of a drug into the market and the description of withdrawal symptoms, caution is needed with the use of newer antidepressants and antipsychotics. Within medication classes, alprazolam, lorazepam, triazolam, paroxetine, venlafaxine, fluphenazine, perphenazine, clozapine, and quetiapine are more likely to induce withdrawal. The likelihood of withdrawal manifestations that may be severe and persistent should thus be taken into account in clinical practice and also in children and adolescents.
Overview
CoChat Summary
TL;DR
This overview applies Chouinard and Chouinard’s diagnostic criteria to withdrawal after decrease, discontinuation, or switch of psychotropic medications, distinguishing new withdrawal symptoms, rebound symptoms, and persistent post-withdrawal disorders. It concludes that all reviewed drug classes may induce withdrawal and rebound even with slow tapering, but SSRIs, SNRIs, and antipsychotics are consistently associated with persistent post-withdrawal disorders and potentially high severity, whereas benzodiazepine discontinuation distress appears short-lived.
Key findings
- Withdrawal reactions can occur after abrupt discontinuation or gradual tapering; prevalence was reported as 54% among adults with serious mental illness, and antidepressant withdrawal incidence ranged from 27 to 86% (weighted average 56%). New withdrawal symptoms peak at 36–96 h, last up to 6 weeks, and are usually reversible; rebound symptoms return original symptoms at greater intensity; persistent post-withdrawal disorders last >6 weeks and are potentially irreversible.
- SSRIs, SNRIs, and antipsychotics were consistently associated with persistent post-withdrawal disorders and increased severity, including altered clinical course. Venlafaxine withdrawal rates ranged from 23 to 78%, and levomilnacipran from 9 to 10%. Antipsychotic supersensitivity psychosis prevalence was reported as 65% in a long-acting injectable risperidone study, 26.5% in a retrospective aripiprazole-switch study, and 72% in treatment-resistant schizophrenia patients treated with second-generation antipsychotics.
- Benzodiazepine new withdrawal symptoms are generally mild, transient, and subside within 2–4 weeks; 75% of patients withdrawn after long-term benzodiazepine use developed new withdrawal symptoms regardless of rapid or slow elimination. Rebound anxiety occurred in 5 of 7 (71.4%) bromazepam-treated patients versus 2 of 7 (28.6%) diazepam-treated patients. Persistent post-withdrawal disorders after long-term benzodiazepine use are described, but the literature is “hardly existent.”
- Ketamine and probably its derivatives may be classified as high risk for dependence and addiction; new withdrawal symptoms typically begin within 24 h, last approximately 3 days, and may persist for 2 weeks. Lithium withdrawal evidence is weak and ambiguous, and data on mood stabilizers are limited.
Methods
- Overview/review of the literature; MEDLINE was searched from inception to January 2020, with manual searching of reference lists and relevant reviews. Search terms combined “discontinuation/withdrawal” with drug-class terms (benzodiazepine, Z-drug, antidepressant, ketamine/esketamine, antipsychotic/neuroleptic, lithium, mood stabilizer).
- Eligible articles were English, peer-reviewed papers reporting data on adult subjects who decreased, discontinued, or switched psychotropic medications. Titles and abstracts were screened by 1 reviewer; potentially relevant full reports were independently assessed by 2 reviewers to consensus.
- Withdrawal symptoms were categorized using a previously used antidepressant discontinuation categorization (general, cardiovascular, gastrointestinal, genitourinary, sensory-related, neuromuscular, sexual, and central nervous system symptoms) and classified according to Chouinard and Chouinard’s criteria for new withdrawal symptoms, rebound symptoms, and persistent post-withdrawal disorders.
Limitations
- Stated: evidence for lithium withdrawal is weak and ambiguous; literature on persistent post-withdrawal disorders after long-term benzodiazepine use is hardly existent, and no studies were found on managing benzodiazepine persistent post-withdrawal disorders. No persistent post-withdrawal data are published for Z-drugs, and data are limited for newer antidepressants, carbamazepine, valproate, and lamotrigine; no rebound or persistent post-withdrawal data are available for mood stabilizers.
- Stated: proposed management strategies for SSRI/SNRI withdrawal—including hyperbolically decreasing dose patterns, multistep dose reduction, and Fava and Belaise’s pharmacological/non-pharmacological strategies—need testing in randomized controlled trials. One group CBT trial found only 37% (n = 26) discontinued antidepressants and 28% (n = 20) discontinued without recurrence, though timing and sample vulnerability may have contributed.
- Evident: this is a narrative overview rather than a systematic review or meta-analysis; no formal quality appraisal or risk-of-bias assessment is described, title/abstract screening was done by one reviewer, and conclusions often rely on case reports, online reports, and limited controlled data. The authors also note a lag phase between drug marketing and description of withdrawal symptoms, which limits certainty for newer agents.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
37 Valid · 35 Not valid · 86 Not checked · 19 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“This was confirmed by other studies [53-59].”
What the sources say
- Not checked — no full text of the sourcecites [53] source
- Not checked — no full text of the sourcecites [54] source
- Not checked — no full text of the sourcecites [55] source
- Not checked — no full text of the sourcecites [56] source
- Disputedcites [57] sourceExperimental — accuracy not yet measured
The Discussion (page not specified in our copy) says the study found no evidence of rebound insomnia after abrupt withdrawal of temazepam. Although this paper evaluated a short-term protocol, it does not confirm the attributed finding; it reports the opposite for the benzodiazepine it studied. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [58] source
- Disputedcites [59] sourceExperimental — accuracy not yet measured
The Design section describes nine nights of temazepam followed by three placebo recovery nights. Rather than confirming rebound insomnia after cessation, the Discussion (p. 695) says there was “no consistent disruption of sleep” and that mean sleep time during recovery was similar to baseline, although four of 12 patients had some disturbed recovery nights. (LLM, conf=0.89)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Recently, it has been described the case of a patient in which PSSD symptoms were part of a broader syndrome which was diagnosed as persistent post-withdrawal disorder [129].”
What the sources say
- Could not verifycites [129] sourceExperimental — accuracy not yet measured
The Discussion > Discontinuation symptoms passage concerns ketamine withdrawal, not PSSD or a diagnosis of persistent post-withdrawal disorder. Searches for those terms and for a patient case found no passage in our copy addressing the claimed case. (LLM, conf=0.76)
plainstates an associationSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“One study found acute dystonia as new withdrawal symptom resulting from abrupt discontinuation of bupropion [105].”
What the sources say
- Could not verifycites [105] sourceExperimental — accuracy not yet measured
The Method and Results (pages unavailable) describe withdrawal reports involving SSRIs and SNRIs, not bupropion. A search for bupropion, acute dystonia, and movement disorders found no passage addressing the claimed symptom after abrupt bupropion discontinuation. (LLM, conf=0.76)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The evidence for withdrawal after lithium decrease or discontinuation is weak and ambiguous.”
What the sources say
- Could not verifycites [173] sourceExperimental — accuracy not yet measured
Section 2.1 mentions cognitive impairments with lithium and reports withdrawal reactions across psychotropic drugs, but does not assess the evidence for withdrawal specifically after lithium dose reduction or discontinuation. A search for lithium found no passage characterizing that evidence as weak or ambiguous; page numbers were unavailable in our copy. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Persistent post-withdrawal disorders, that is a condition in which rebound symptoms and/or new withdrawal symptoms and/or emerging new psychotic symptoms of another type, such as disorganized behavior, persist longer than 6 weeks, have been described after discontinuation of antipsychotics.”
What the sources say
- Could not verifycites [21] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [22] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [150] source
- Not checked — no full text of the sourcecites [151] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
91 more claims · 25 with their cited sources checked
Create a free account to see all 177 claims and every source verdict.
- Probably not a substantial claim. 31
- It may state two separate claims as one. 56
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Longer-term BZD use and use of high-dose, rapid-acting BZDs increase the risk of protracted withdrawal”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [130]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Protracted symptoms persist beyond the expected elimination of the BZD from a patient’s system after discontinuation (e.g., 4–6 weeks), with some patients experiencing these symptoms for months or years.78,130,132”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [130]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In this respect, antidepressants do not differ from other dependence-forming central nervous system (CNS) drugs like benzodiazepines, opioids, gabapentinoids, or psychostimulants.3,19–22”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As with other psychotropics, the potential for antidepressant PWS is embedded in pharmacodynamic adaptations and possibly irreversible neurophysiological alterations following prolonged drug exposure.19,20,31”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Untreated symptoms may be mild and resolve spontaneously in 1–3 weeks; in other cases they may persist for months or even years,40–45 leading to what has been defined as persistent post-withdrawal disorder.”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [45]
Experimental — accuracy not yet measured
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies
Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998) · JAMA · doi:10.1001/jama.279.15.1200 · Cited by 4,807
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Reed, G. M., First, M. B., Kogan, C. S., Hyman, S. E., Gureje, O., Gaebel, W., Maj, M., Stein, D. J., Maercker, A., Tyrer, P., et al. (2019) · World Psychiatry · doi:10.1002/wps.20611 · Cited by 765
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Management of Drug and Alcohol Withdrawal
Kosten, T. R., & O'Connor, P. G. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020617 · Cited by 563
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Davies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.08.027 · Cited by 387
Withdrawal Reaction after Long-Term Therapeutic Use of Benzodiazepines
Busto, U., Sellers, E. M., Naranjo, C. A., Cappell, H., Sanchez-Craig, M., & Sykora, K. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610023151403 · Cited by 369
Withdrawal from long-term benzodiazepine treatment
Petursson, H., & Lader, M. H. (1981) · BMJ · doi:10.1136/bmj.283.6292.643 · Cited by 367
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Goodwin, G. M., Emsley, R., Rembry, S., Rouillon, F., & the Agomelatine Study Group (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04548 · Cited by 340
Esketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class
Kim, J., Farchione, T., Potter, A., Chen, Q., & Temple, R. (2019) · New England Journal of Medicine · doi:10.1056/nejmp1903305 · Cited by 333
Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics
(1980) · American Journal of Psychiatry · doi:10.1176/ajp.137.1.16 · Cited by 301
Self-citationParadoxical reactions to benzodiazepines: literature review and treatment options
Mancuso, C. E., Tanzi, M. G., & Gabay, M. (2004) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.13.1177.38089 · Cited by 298
Benzodiazepine withdrawal symptoms and propranolol
TYRER, P. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92861-0 · Cited by 297
(2004) · PubMed · Cited by 296
Self-citationAntidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Tapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477313 · Cited by 270
Self-citation(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.10.1485 · Cited by 263
Chouinard, G., Annable, L., Fontaine, R., & Solyom, L. (1982) · Psychopharmacology · doi:10.1007/bf00464571 · Cited by 256
Self-citationThe benzodiazepine withdrawal syndrome
PÉTURSSON, H. (1994) · Addiction · doi:10.1111/j.1360-0443.1994.tb03743.x · Cited by 246
Seeman, P., & Tallerico, T. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.6.876 · Cited by 237
Moncrieff, J. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00787.x · Cited by 231
Neuroleptic-induced supersensitivity psychosis
(1978) · American Journal of Psychiatry · doi:10.1176/ajp.135.11.1409 · Cited by 224
Self-citationCan long-term treatment with antidepressant drugs worsen the course of depression?
Fava, G. A. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0204 · Cited by 223
Sim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv076 · Cited by 218
Antidepressant Discontinuation Syndromes: Clinical Relevance, Prevention and Management
Haddad, P. M. (2001) · Drug Safety · doi:10.2165/00002018-200124030-00003 · Cited by 214
Discontinuation Symptoms After Treatment With Serotonin Reuptake Inhibitors: A Literature Review
Zajecka, J., Tracy, K. A., & Mitchell, S. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0702 · Cited by 209
Fava, G. A., Benasi, G., Lucente, M., Offidani, E., Cosci, F., & Guidi, J. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491524 · Cited by 209
Self-citationAtypical Antipsychotics Part I: Pharmacology, Pharmacokinetics, and Efficacy
Markowitz, J. S., Brown, C. S., & Moore, T. R. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.17215 · Cited by 208
Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria.
(2000) · PubMed Central · Cited by 207
Strategies for discontinuing long-term benzodiazepine use: Meta-analysis
Voshaar, R. C. O., Couvée, J. E., Van Balkom, A. J. L. M., Mulder, P. G. H., & Zitman, F. G. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.189.3.213 · Cited by 205
Rebound Insomnia: A New Clinical Syndrome
Kales, A., Scharf, M. B., & Kales, J. D. (1978) · Science · doi:10.1126/science.684426 · Cited by 200
Montgomery, S. A., Kennedy, S. H., Burrows, G. D., Lejoyeux, M., & Hindmarch, I. (2004) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000137184.64610.c8 · Cited by 196
Amnestic sleep-related eating disorder associated with zolpidem
Morgenthaler, T. I., & Silber, M. H. (2002) · Sleep Medicine · doi:10.1016/s1389-9457(02)00007-2 · Cited by 185
Michelson, D., Fava, M., Amsterdam, J., Apter, J., Londborg, P., Tamura, R., & Tepner, R. G. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.4.363 · Cited by 181
Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.7.848 · Cited by 176
Self-citation(2003) · Europe PMC (PubMed Central) · Cited by 176
Allgulander, C., Hackett, D., & Salinas, E. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.1.15 · Cited by 175
Ketamine and other glutamate receptor modulators for depression in adults
Caddy, C., Amit, B. H., McCloud, T. L., Rendell, J. M., Furukawa, T. A., McShane, R., Hawton, K., & Cipriani, A. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011612.pub2 · Cited by 174
Protracted withdrawal syndromes from benzodiazepines
Ashton, H. (1991) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(91)90023-4 · Cited by 170
Chouinard, G., & Chouinard, V.-A. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000112883 · Cited by 168
Self-citationPost-SSRI Sexual Dysfunction: A Literature Review
Bala, A., Nguyen, H. M. T., & Hellstrom, W. J. G. (2018) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2017.07.002 · Cited by 167
Offidani, E., Guidi, J., Tomba, E., & Fava, G. A. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000353198 · Cited by 166
BENZODIAZEPINES: USE, OVERUSE, MISUSE, ABUSE?
(1973) · The Lancet · doi:10.1016/s0140-6736(73)90405-4 · Cited by 165
New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal
Chouinard, G., & Chouinard, V.-A. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000371865 · Cited by 164
Self-citationPetursson, H., & Lader, M. H. (1981) · British Journal of Addiction · doi:10.1111/j.1360-0443.1981.tb00218.x · Cited by 163
LENGTH OF TREATMENT WITH ANXIOLYTIC SEDATIVES AND RESPONSE TO THEIR SUDDEN WITHDRAWAL
Covi, L., Lipman, R. S., Pattison, J. H., Derogatis, L. R., & Uhlenhuth, E. H. (1973) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1973.tb04398.x · Cited by 162
Antidepressant discontinuation syndromes
Haddad, P. M., Anderson, I., & Rosenbaum, J. (2004) · Adverse Syndromes and Psychiatric Drugs · doi:10.1093/med/9780198527480.003.0010 · Cited by 160
The Public and the Opioid-Abuse Epidemic
Blendon, R. J., & Benson, J. M. (2018) · New England Journal of Medicine · doi:10.1056/nejmp1714529 · Cited by 158
The mechanisms of tolerance in antidepressant action
Fava, G. A., & Offidani, E. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.026 · Cited by 158
Voshaar, R. C. O., Gorgels, W. J. M. J., Mol, A. J. J., Van Balkom, A. J. L. M., Van De Lisdonk, E. H., Breteler, M. H. M., Van Den Hoogen, J. M., & Zitman, F. G. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.6.498 · Cited by 154
Soldatos, C. R., Dikeos, D. G., & Whitehead, A. (1999) · International Clinical Psychopharmacology · doi:10.1097/00004850-199909000-00004 · Cited by 154
Batelaan, N. M., Bosman, R. C., Muntingh, A., Scholten, W. D., Huijbregts, K. M., & van Balkom, A. J. L. M. (2017) · BMJ · doi:10.1136/bmj.j3927 · Cited by 153
Factors related to tardive dyskinesia
(1979) · American Journal of Psychiatry · doi:10.1176/ajp.136.1.79 · Cited by 150
Self-citationBehavioral toxicity of antipsychotic drugs.
Putten, T. V., & Marder, S. R. (1987) · PubMed · Cited by 144
Bandelow, B., Chouinard, G., Bobes, J., Ahokas, A., Eggens, I., Liu, S., & Eriksson, H. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990423 · Cited by 142
Self-citationAnxiety caused by a short-life hypnotic.
Morgan, K., & Oswald, I. (1982) · BMJ · doi:10.1136/bmj.284.6320.942 · Cited by 137
The Nonmedical Use of Ketamlne, Part Two: A Review of Problent Use and Dependence
Jansen, K. L. R., & Darracot-Cankovic, R. (2001) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2001.10400480 · Cited by 137
On the supersensitivity of dopamine receptors, induced by neuroleptics
Christensen, A. V., Fjalland, B., & Nielsen, I. M. (1976) · Psychopharmacology · doi:10.1007/bf00423298 · Cited by 134
Gosselin, P., Ladouceur, R., Morin, C. M., Dugas, M. J., & Baillargeon, L. (2006) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.74.5.908 · Cited by 122
The Clinimetric Approach to Psychological Assessment: A Tribute to Per Bech, MD (1942–2018)
Fava, G. A., Carrozzino, D., Lindberg, L., & Tomba, E. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000493746 · Cited by 119
WITHDRAWAL SYMPTOMS FOLLOWING DISCONTINUATION OF IMIPRAMINE THERAPY
KRAMER, J. C., KLEIN, D. F., & FINK, M. (1961) · American Journal of Psychiatry · doi:10.1176/ajp.118.6.549 · Cited by 113
Cerovecki, A., Musil, R., Klimke, A., Seemüller, F., Haen, E., Schennach, R., Kühn, K.-U., Volz, H.-P., & Riedel, M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0079-5 · Cited by 112
Murphy, S. M., & Tyrer, P. (1991) · British Journal of Psychiatry · doi:10.1192/bjp.158.4.511 · Cited by 104
Nielsen, M., Hansen, E. H., & Gøtzsche, P. C. (2012) · Addiction · doi:10.1111/j.1360-0443.2011.03686.x · Cited by 103
Low-dose dependence in chronic benzodiazepine users: a preliminary report on 119 patients.
Rickels, K., Wg, C., Schweizer, E. E., Swenson, C., & Rb, F. (1986) · PubMed · Cited by 102
Ketamine associated psychedelic effects and dependence.
Dk, L. (2003) · PubMed · Cited by 100
Hypnotic Efficacy of Triazolam: Sleep Laboratory Evaluation of Intermediate‐Term Effectiveness
KALES, A., KALES, J. D., BIXLER, E. O., SCHARF, M. B., & RUSSEK, E. (1976) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1976.tb02414.x · Cited by 99
MITLER, M. M., SEIDEL, W. F., DEN HOED, J. V., GREENBLATT, D. J., & DEMENT, W. C. (1984) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198402000-00002 · Cited by 98
Effect of Gradual Withdrawal on the Rebound Sleep Disorder after Discontinuation of Triazolam
Greenblatt, D. J., Harmatz, J. S., Zinny, M. A., & Shader, R. I. (1987) · New England Journal of Medicine · doi:10.1056/nejm198709173171202 · Cited by 96
Rational Use of Antidepressant Drugs
Fava, G. A. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000362803 · Cited by 95
Otto, M. W., McHugh, R. K., Simon, N. M., Farach, F. J., Worthington, J. J., & Pollack, M. H. (2010) · Behaviour Research and Therapy · doi:10.1016/j.brat.2010.04.002 · Cited by 95
Hypnotics in Insomnia: The Experience of Zolpidem
MacFarlane, J., Morin, C. M., & Montplaisir, J. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.09.017 · Cited by 94
Stein, D. J., Ahokas, A., Albarran, C., Olivier, V., & Allgulander, C. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07493 · Cited by 94
Fava, G. A., Guidi, J., Rafanelli, C., & Rickels, K. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000480038 · Cited by 93
Persistent Sexual Side Effects after SSRI Discontinuation
Csoka, A. B., & Shipko, S. (2006) · Psychotherapy and Psychosomatics · doi:10.1159/000091777 · Cited by 92
Marks, J. (1978) · doi:10.1007/978-94-011-6203-6 · Cited by 92
Rebound insomnia after only brief and intermittent use of rapidly eliminated benzodiazepines
Kales, A., Manfredi, R. L., Vgontzas, A. N., Bixler, E. O., Vela-Bueno, A., & Fee, E. C. (1991) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1991.55 · Cited by 90
The reappraisal of benzodiazepines in the treatment of anxiety and related disorders
Starcevic, V. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.963057 · Cited by 90
Nitrazepam: lastingly effective but trouble on withdrawal.
Adam, K., Adamson, L., Brezinova, V, & Hunter, W. M. (1976) · BMJ · doi:10.1136/bmj.1.6025.1558 · Cited by 90
Benzodiazepine Dependency Syndromes
Smith, D. E., & Wesson, D. R. (1983) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1983.10472127 · Cited by 90
ECT continuation and maintenance in a patient with psychosis and mental disability.
Chouinard, G., Beauclair, L., & Bélanger, M. C. (1998) · PubMed · Cited by 89
Self-citationLerner, A., & Klein, M. (2019) · Brain Communications · doi:10.1093/braincomms/fcz025 · Cited by 89
Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal
Ekblom, B., Eriksson, K., & Lindstr�m, L. H. (1984) · Psychopharmacology · doi:10.1007/bf00464798 · Cited by 88
Benzodiazepine withdrawal: a review of the evidence.
Noyes, R., Garvey, M. J., Cook, B. L., & Perry, P. J. (1988) · PubMed · Cited by 87
Gender differences in subjective discontinuation symptoms associated with ketamine use
Chen, W.-Y., Huang, M.-C., & Lin, S.-K. (2014) · Substance Abuse Treatment, Prevention, and Policy · doi:10.1186/1747-597x-9-39 · Cited by 87
Pal, H. R., Berry, N., Kumar, R., & Ray, R. (2002) · Anaesthesia and Intensive Care · doi:10.1177/0310057x0203000323 · Cited by 87
Iatrogenic Factors in Psychopathology
Fava, G. A., & Rafanelli, C. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000500151 · Cited by 82
Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia
Suzuki, T., Kanahara, N., Yamanaka, H., Takase, M., Kimura, H., Watanabe, H., & Iyo, M. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.02.021 · Cited by 81
Healy, D., Le Noury, J., & Mangin, D. (2018) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-180744 · Cited by 81
Fava, G. A., Bernardi, M., Tomba, E., & Rafanelli, C. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706007462 · Cited by 80
Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant
Zhu, W., Ding, Z., Zhang, Y., Shi, J., Hashimoto, K., & Lu, L. (2016) · Neuroscience Bulletin · doi:10.1007/s12264-016-0081-2 · Cited by 80
A case of ketamine dependence with discontinuation symptoms
Critchlow, D. G. (2006) · Addiction · doi:10.1111/j.1360-0443.2006.01494.x · Cited by 79
Discontinuing Antidepressant Drugs: Lesson from a Failed Trial and Extensive Clinical Experience
Fava, G. A., & Belaise, C. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000492693 · Cited by 77
Thornlow, D. K., Anderson, R., & Oddone, E. (2009) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2009.06.015 · Cited by 74
Benzodiazepine Dependence: Avoidance and Withdrawal
Marriott, S., & Tyrer, P. (1993) · Drug Safety · doi:10.2165/00002018-199309020-00003 · Cited by 73
Do Antidepressant and Antianxiety Drugs Increase Chronicity in Affective Disorders?
Fava, G. A. (2010) · Psychotherapy and Psychosomatics · doi:10.1159/000288880 · Cited by 73
When Discontinuing SSRI Antidepressants Is a Challenge: Management Tips
Jha, M. K., Rush, A. J., & Trivedi, M. H. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18060692 · Cited by 73
Dilsaver, S. C., & Greden, J. F. (1984) · Brain Research Reviews · doi:10.1016/0165-0173(84)90028-6 · Cited by 73
A comparison of the effects of flurazepam 30 mg and triazolam 0.5 mg on the sleep of insomniacs
Vogel, G. W., Barker, K., Gibbons, P., & Thurmond, A. (1976) · Psychopharmacology · doi:10.1007/bf00428706 · Cited by 72
Mental Pain as a Transdiagnostic Patient-Reported Outcome Measure
Fava, G. A., Tomba, E., Brakemeier, E.-L., Carrozzino, D., Cosci, F., Eöry, A., Leonardi, T., Schamong, I., & Guidi, J. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000504024 · Cited by 70
Self-citationWithdrawing Benzodiazepines in Patients With Anxiety Disorders
Lader, M., & Kyriacou, A. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-015-0642-5 · Cited by 67
Fiorillo, A., Dell'Osso, B., Albert, U., Atti, A. R., Carmassi, C., Carrà, G., Cosci, F., Del Vecchio, V., Di Nicola, M., Ferrari, S., et al. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s83130 · Cited by 67
Self-citationComparison of short and long half-life benzodiazepine hypnotics: Triazolam and quazepam
Kales, A., Bixler, E. O., Vela-Bueno, A., Soldatos, C. R., Nikiaus, D. E., & Manfredi, R. L. (1986) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1986.194 · Cited by 66
Discontinuing Psychiatric Medications: A Survey of Long-Term Users
Ostrow, L., Jessell, L., Hurd, M., Darrow, S. M., & Cohen, D. (2017) · Psychiatric Services · doi:10.1176/appi.ps.201700070 · Cited by 62
Quazepam and flurazepam: Long-term use and extended withdrawal
Kales, A., Bixler, E. O., Soldatos, C. R., Vela-Bueno, A., Jacoby, J., & Kales, J. D. (1982) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1982.236 · Cited by 62
Margolese, H. C., Chouinard, G., Beauclair, L., & Bélanger, M.-C. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200208000-00003 · Cited by 61
Self-citationCognitive toxicity of pharmacotherapeutic agents used in social anxiety disorder
Hindmarch, I. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02085.x · Cited by 61
Withdrawal phenomena associated with antidepressant and antipsychotic agents
Dilsaver, S. C. (1994) · Drug Safety · doi:10.2165/00002018-199410020-00002 · Cited by 60
HYPNOTIC EFFICACY OF TEMAZEPAM: A LONG‐TERM SLEEP LABORATORY EVALUATION
MITLER, M. M., CARSKADON, M. A., PHILLIPS, R. L., STERLING, W. R., ZARCONE, V. P., SPIEGEL, R., GUILLEMINAULT, C., & DEMENT, W. C. (1979) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1979.tb00459.x · Cited by 60
BIXLER, E. O., KALES, A., SOLDATOS, C. R., SCHARF, M. B., & KALES, J. D. (1978) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1978.tb02430.x · Cited by 60
Rothschild, A. J., Raskin, J., Wang, C.-N., Marangell, L. B., & Fava, M. (2014) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2013.08.008 · Cited by 59
Eszopiclone: A Review of Its Use in the Treatment of Insomnia
Hair, P. I., McCormack, P. L., & Curran, M. P. (2008) · Drugs · doi:10.2165/00003495-200868100-00005 · Cited by 59
Cloos, J.-M., Bocquet, V., Rolland-Portal, I., Koch, P., & Chouinard, G. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000434755 · Cited by 57
Self-citationA Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder
Chouinard, G., Saxena, B., Bélanger, M.-C., Ravindran, A., Bakish, D., Beauclair, L., Morris, P., Vasavan Nair, N. P., Manchanda, R., Reesal, R., et al. (1999) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00188-8 · Cited by 57
Self-citationFallon, P., & Dursun, S. M. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881109359097 · Cited by 56
Abrupt lithium discontinuation in manic‐depressive patients
Christodoulou, G. N., & Lykouras, E. P. (1982) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1982.tb00852.x · Cited by 56
Kimura, H., Kanahara, N., Komatsu, N., Ishige, M., Muneoka, K., Yoshimura, M., Yamanaka, H., Suzuki, T., Komatsu, H., Sasaki, T., et al. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.02.022 · Cited by 55
Behavioral Toxicity Revisited: Iatrogenic Comorbidity in Psychiatric Evaluation and Treatment
Fava, G. A., Cosci, F., Offidani, E., & Guidi, J. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000570 · Cited by 55
Self-citationTakase, M., Kanahara, N., Oda, Y., Kimura, H., Watanabe, H., & Iyo, M. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115570083 · Cited by 54
Assessing medication burden and polypharmacy: finding the perfect measure
Gnjidic, D., Tinetti, M., & Allore, H. G. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1301206 · Cited by 54
SSRI and SNRI withdrawal symptoms reported on an internet forum
Stockmann, T., Odegbaro, D., Timimi, S., & Moncrieff, J. (2018) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-180018 · Cited by 54
Duration of Initial Antidepressant Treatment and Subsequent Relapse of Major Depression
Baldessarini, R. J., Lau, W. K., Sim, J., Sum, M. Y., & Sim, K. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000263 · Cited by 52
Effects of Treatment Discontinuation in Clinical Psychopharmacology
Baldessarini, R. J., & Tondo, L. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000497334 · Cited by 52
Clinical Pharmacopsychology: Conceptual Foundations and Emerging Tasks
Fava, G. A., Tomba, E., & Bech, P. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000458458 · Cited by 52
New nomenclature for drug-induced movement disorders including tardive dyskinesia.
Chouinard, G. (2004) · PubMed · Cited by 50
Self-citationClorazepate and lorazepam: clinical improvement and rebound anxiety
(1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.3.312 · Cited by 50
Antidepressant-Withdrawal Mania: A Critical Review and Synthesis of the Literature
Andrade, C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0716 · Cited by 49
Physical dependence on benzodiazepines: differences within the class
Wolf, B., & Griffiths, R. R. (1991) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(91)90044-y · Cited by 49
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.5.779a · Cited by 49
Ghaemi, S. N. (2002) · doi:10.1201/b15278 · Cited by 48
KAMAYA, H., & KRISHNA, P. R. (1987) · Anesthesiology · doi:10.1097/00000542-198711000-00054 · Cited by 48
Fallon, P., Dursun, S., & Deakin, B. (2012) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125311431105 · Cited by 47
Belaise, C., Gatti, A., Chouinard, V.-A., & Chouinard, G. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000341178 · Cited by 45
Self-citationBelaise, C., Gatti, A., Chouinard, V.-A., & Chouinard, G. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000362317 · Cited by 44
Self-citationReisman, Y. (2020) · BMJ · doi:10.1136/bmj.m754 · Cited by 44
Chouinard, G., Labonte, A., Fontaine, R., & Annable, L. (1983) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(83)90043-x · Cited by 43
Self-citationLorazepam—Efficacy, side effects, and rebound phenomena
Scharf, M. B., & Jacoby, J. A. (1982) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1982.27 · Cited by 43
Adverse Drug Effects and the Need for Drug Information
Enlund, H., Vainio, K., Wallenius, S., & Poston, J. W. (1991) · Medical Care · doi:10.1097/00005650-199106000-00014 · Cited by 43
Clonazepam in the treatment of patients with recurrent panic attacks.
Beaudry, P., Fontaine, R., Chouinard, G., & Annable, L. (1986) · PubMed · Cited by 42
Self-citationInnovative trends in the design of therapeutic trials in psychopharmacology and psychotherapy
Fava, G. A., Tomba, E., & Tossani, E. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.10.014 · Cited by 41
Bahrick, A. S. (2008) · The Open Psychology Journal · doi:10.2174/1874350100801010042 · Cited by 41
Clonazepam for the Treatment of Panic Disorder
E. Nardi, A., Machado, S., Ferreira Almada, L., Paes, F., Cardoso Silva, A., Jose Marques, R., Amrein, R., C. Freire, R., Martin-Santos, R., Cosci, F., et al. (2013) · Current Drug Targets · doi:10.2174/1389450111314030007 · Cited by 40
Self-citationRebound insomnia after hypnotic withdrawal in insomniac outpatients
Hajak, G., Clarenbach, P., Fischer, W., Rodenbeck, A., Bandelow, B., Broocks, A., & Rüther, E. (1998) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s004060050032 · Cited by 39
Récalt, A. M., & Cohen, D. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000496734 · Cited by 38
FONTAINE, R., BEAUDRY, P., MORVAN, P. L., BEAUCLAIR, L., & CHOUINARD, G. (1990) · International Clinical Psychopharmacology · doi:10.1097/00004850-199007000-00002 · Cited by 37
Self-citationWhat Is New about New Antidepressants?
Dubovsky, S. L. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000488945 · Cited by 37
Is There a Lithium Withdrawal Syndrome?
Schou, M. (1993) · The British Journal of Psychiatry · doi:10.1192/bjp.163.4.514 · Cited by 36
Witkin, J. M. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172854 · Cited by 36
International Task Force on Benzodiazepines
Balon, R., Chouinard, G., Cosci, F., Dubovsky, S. L., Fava, G. A., Freire, R. C., Greenblatt, D. J., Krystal, J. H., Nardi, A. E., Rickels, K., et al. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000489538 · Cited by 35
Self-citationScholten, W. D., Batelaan, N. M., van Oppen, P., Smit, J. H., Hoogendoorn, A. W., van Megen, H. J. G. M., Cath, D. C., & van Balkom, A. J. L. M. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000489498 · Cited by 33
Nighttime and daytime efficacy of flurazepam and oxazepam in chronic insomnia
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.2.191 · Cited by 33
Antidepressant withdrawal syndromes: phenomenology and pathophysiology
Dilsaver, S. C. (1989) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1989.tb08578.x · Cited by 33
(2006) · PubMed · Cited by 33
Self-citationWithdrawal symptoms from phenytoin, carbamazepine and sodium valproate.
Duncan, J. S., Shorvon, S. D., & Trimble, M. R. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.7.924 · Cited by 33
Benzodiazepines and anxiety sensitivity in panic disorder
Fava, G. A., Grandi, S., Belluardo, P., Savron, G., Raffi, A. R., Conti, S., & Saviotti, F. M. (1994) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(94)90118-x · Cited by 32
Withdrawal and Rebound Symptoms Associated With Abrupt Discontinuation of Venlafaxine
Dallal, A., & Chouinard, G. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199808000-00017 · Cited by 32
Self-citationMental Pain and Euthymia as Transdiagnostic Clinimetric Indices in Primary Care
Guidi, J., Piolanti, A., Gostoli, S., Schamong, I., & Brakemeier, E.-L. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000501622 · Cited by 32
WHITHER KETAMINE AS AN ANTIDEPRESSANT: PANACEA OR TOXIN?: Editorial
Newport, D. J., Schatzberg, A. F., & Nemeroff, C. B. (2016) · Depression and Anxiety · doi:10.1002/da.22535 · Cited by 30
Mechanisms of the development of trazodone withdrawal symptoms
Otani, K., Tanaka, O., Kaneko, S., Ishida, M., Yasui, N., & Fukushima, Y. (1994) · International Clinical Psychopharmacology · doi:10.1097/00004850-199400920-00011 · Cited by 29
Lorazepam: Effects on Sleep and Withdrawal Phenomena
Kales, A., Bixler, E. O., Soldatos, C. R., Jacoby, J. A., & Kales, J. D. (2008) · Pharmacology · doi:10.1159/000138160 · Cited by 29
A Guide to Benzodiazepine Selection. Part I: Pharmacological Aspects *
Teboul, E., & Chouinard, G. (1990) · The Canadian Journal of Psychiatry · doi:10.1177/070674379003500811 · Cited by 28
Self-citationCohen, D., & Recalt, A. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000496733 · Cited by 28
Tapering of SSRI treatment to mitigate withdrawal symptoms
Ruhe, H. G., Horikx, A., van Avendonk, M. J. P., Groeneweg, B. F., & Woutersen-Koch, H. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30182-8 · Cited by 28
Clinical Methodology Matters in Epidemiology: Not All Benzodiazepines Are the Same
Cosci, F., Guidi, J., Balon, R., & Fava, G. A. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000437201 · Cited by 27
Self-citationKimura, H., Kanahara, N., Sasaki, T., Komatsu, N., Ishige, M., Muneoka, K., Ino, H., Yoshimura, K., Yamanaka, H., Suzuki, T., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116655978 · Cited by 26
A Rating Scale for Psychotic Symptoms (RSPS)
Chouinard, G., & Miller, R. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00012-2 · Cited by 26
Self-citation(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.1.108 · Cited by 26
Self-citationA Guide to Benzodiazepine Selection. Part II: Clinical Aspects
Teboul, E., & Chouinard, G. (1991) · The Canadian Journal of Psychiatry · doi:10.1177/070674379103600117 · Cited by 25
Self-citationRebound insomnia in normals and patients with insomnia after abrupt and tapered discontinuation
Roehrs, T., Merlotti, L., Zorick, F., & Roth, T. (1992) · Psychopharmacology · doi:10.1007/bf02245287 · Cited by 25
Zolpidem Dependency and Withdrawal Seizure: A Case Report Study
Javadi, S. A. H. S., Hajiali, F., & Nassiri‐Asl, M. (2014) · Iranian Red Crescent Medical Journal · doi:10.5812/ircmj.19926 · Cited by 25
Effects of lorazepam and its withdrawal on sleep, performance, and subjective state
Walsh, J. K., Schweitzer, P. K., & Parwatikar, S. (1983) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1983.203 · Cited by 24
Rebound anxiety in panic disorder patients treated with shorter-acting benzodiazepines.
Herman, J., Brotman, A. W., & Rosenbaum, J. F. (1987) · PubMed · Cited by 24
Offidani, E., Fava, G. A., & Sonino, N. (2014) · CNS Drugs · doi:10.1007/s40263-014-0184-0 · Cited by 23
Withdrawal symptoms after long-term treatment with low-potency neuroleptics.
Chouinard, G., Bradwejn, J., Annable, L., Jones, B. D. M., & Ross‐Chouinard, A. (1984) · PubMed · Cited by 23
Self-citationAcute dystonia resulting from abrupt bupropion discontinuation
Wang, H.-Y., Chou, W.-J., Huang, T.-Y., & Hung, C.-F. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.12.003 · Cited by 21
Failure to Respond after Reinstatement of Antidepressant Medication: A Systematic Review
Bosman, R. C., Waumans, R. C., Jacobs, G. E., Oude Voshaar, R. C., Muntingh, A. D. T., Batelaan, N. M., & van Balkom, A. J. L. M. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491550 · Cited by 21
Mental Pain Questionnaire: An item response theory analysis
Svicher, A., Romanazzo, S., De Cesaris, F., Benemei, S., Geppetti, P., & Cosci, F. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.02.030 · Cited by 21
Self-citationEarly onset of tardive dyskinesia: case report
(1979) · American Journal of Psychiatry · doi:10.1176/ajp.136.10.1323 · Cited by 20
Self-citationLee, L. H. N., Choi, C., Collier, A. C., Barr, A. M., Honer, W. G., & Procyshyn, R. M. (2015) · CNS Drugs · doi:10.1007/s40263-015-0295-2 · Cited by 19
Nemeroff, C. B. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18010014 · Cited by 19
Cosci, F., Chouinard, G., Chouinard, V.-A., & Fava, G. A. (2018) · Rivista di Psichiatria · doi:10.1708/2891.29158 · Cited by 19
Self-citationTemazepam's efficacy in patients with sleep onset insomnia.
Roehrs, T., Lamphere, J., Paxton, C., Wittig, R., Zorick, F., & Roth, T. (1984) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1984.tb02405.x · Cited by 18
Clewes, J. (2012) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.11br01218 · Cited by 16
DiMascio, A., & Shader, R. I. (1968) · PubMed · Cited by 15
Chouinard, G., Boisvert, D., & Bradwejn, J. (1982) · PubMed Central · Cited by 15
Self-citationLithium discontinuation: Withdrawal or relapse?
Balon, R., Yeragani, V. K., Pohl, R. B., & Gershon, S. (1988) · Comprehensive Psychiatry · doi:10.1016/0010-440x(88)90056-9 · Cited by 14
Flurazepam for Short‐Term Treatment of Complaints of Insomnia
ROEHRS, T., ZORICK, F., KAFFEMAN, M., SICKLESTEEL, J., & ROTH, T. (1982) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1982.tb02677.x · Cited by 14
Venlafaxine withdrawal reactions
Boyd, I. W. (1998) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1998.tb140191.x · Cited by 14
Rebound cardiac arrhythmia after withdrawal from imipramine: a case report
(1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.7.985 · Cited by 14
Self-citationMania After Venlafaxine Withdrawal in a Patient with Generalized Anxiety Disorder
Khazaal, Y. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1h504 · Cited by 13
Discontinuing Paroxetine: A Personal Account
Shoenberger, D. (2002) · Psychotherapy and Psychosomatics · doi:10.1159/000063650 · Cited by 12
Chen, M.-J., Zhang, W.-J., Guo, Z.-L., Zhang, W.-H., Chai, Y., & Li, Y.-W. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2013.12.013 · Cited by 12
Benzodiazepine withdrawal seizures and management.
Hu, X. (2011) · PubMed · Cited by 12
Withdrawal syndrome in a depressed patient treated with trazodone
(1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.9.1195a · Cited by 12
A Rating Scale for Psychotic Symptoms (RSPS):
Chouinard, G., & Miller, R. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00013-4 · Cited by 11
Self-citation
Cited by
Benzodiazepines Remain Important Therapeutic Options in Psychiatric Practice
Dubovsky, S. L., & Marshall, D. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000524400 · Cited by 171
Wilkinson, S. T., Rhee, T. G., Joormann, J., Webler, R., Ortiz Lopez, M., Kitay, B., Fasula, M., Elder, C., Fenton, L., & Sanacora, G. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000517074 · Cited by 108
Long-term use of benzodiazepines in chronic insomnia: a European perspective
Soyka, M., Wild, I., Caulet, B., Leontiou, C., Lugoboni, F., & Hajak, G. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1212028 · Cited by 121
Cerne, R., LIPPA, A. S., Poe, M. M., Smith, J. L., Jin, X., Ping, X., Golani, L. K., Cook, J. M., & Witkin, J. M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108035 · Cited by 95
Clayton, A. H., Lasser, R., Parikh, S. V., Iosifescu, D. V., Jung, J., Kotecha, M., Forrestal, F., Jonas, J., Kanes, S. J., & Doherty, J. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220459 · Cited by 87
Metadata
- Authors
- Cosci, F., & Chouinard, G.
- Affiliations
- Maastricht University (NL)
- McGill University (CA)
- ORCID
- Cosci, Fiammetta
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2020
- Volume
- 89
- Issue
- 5
- Pages
- 283-306
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W3014423675
- Cited by
- 265
- References
- 219
- Citations by year
- 2026: 35 · 2025: 34 · 2024: 53 · 2023: 45 · 2022: 37 · 2021: 45 · 2020: 16
- FWCI
- 4.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- karger.com/pages/terms-and-conditions (vor)
- karger.com/pages/terms-and-conditions (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Florence Research (University of Florence) (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- drug discontinuation, benzodiazepines, antidepressants, ketamine, antipsychotic drugs, lithium, mood stabilizers, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, alprazolam, lorazepam, triazolam, paroxetine, venlafaxine, fluphenazine, perphenazine, clozapine, quetiapine, drug addiction, children and adolescents
- MeSH terms
- Mental Disorders, Humans, Psychotropic Drugs, Substance Withdrawal Syndrome, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.